X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2222) 2222
animals (1891) 1891
oligopeptides - pharmacokinetics (1396) 1396
male (1295) 1295
oligopeptides - chemistry (1010) 1010
mice (984) 984
female (936) 936
pharmacology & pharmacy (934) 934
oligopeptides - pharmacology (863) 863
oligopeptides - administration & dosage (616) 616
oligopeptides - therapeutic use (613) 613
rats (588) 588
cell line, tumor (542) 542
peptides (470) 470
tissue distribution (463) 463
adult (446) 446
middle aged (436) 436
oligopeptides - metabolism (418) 418
pharmacokinetics (395) 395
biochemistry & molecular biology (345) 345
atazanavir sulfate (339) 339
cancer (334) 334
dose-response relationship, drug (298) 298
oligopeptides - adverse effects (296) 296
oncology (296) 296
mice, nude (286) 286
chemistry, multidisciplinary (284) 284
amino acid sequence (279) 279
hiv infections - drug therapy (265) 265
drug delivery systems (248) 248
treatment outcome (240) 240
analysis (233) 233
aged (227) 227
rats, sprague-dawley (227) 227
oligopeptides - blood (222) 222
oligopeptides - chemical synthesis (222) 222
research (219) 219
therapy (219) 219
chemistry, medicinal (214) 214
mice, inbred balb c (213) 213
nanoparticles (212) 212
pyridines - pharmacokinetics (210) 210
tumors (198) 198
radiopharmaceuticals - pharmacokinetics (197) 197
in-vitro (196) 196
drug therapy, combination (194) 194
expression (194) 194
drug interactions (192) 192
in-vivo (191) 191
oligopeptides (191) 191
infectious diseases (190) 190
proteins (180) 180
drugs (179) 179
drug therapy (169) 169
antineoplastic agents - pharmacology (166) 166
antineoplastic agents - pharmacokinetics (165) 165
protease inhibitors (163) 163
health aspects (161) 161
structure-activity relationship (159) 159
pyridines - therapeutic use (157) 157
molecular sequence data (156) 156
cells (151) 151
apoptosis (150) 150
xenograft model antitumor assays (149) 149
integrin alphavbeta3 - metabolism (147) 147
peptide (146) 146
cells, cultured (145) 145
drug-delivery (145) 145
kinetics (145) 145
disease models, animal (143) 143
time factors (143) 143
angiogenesis (142) 142
atazanavir (142) 142
ligands (141) 141
pharmacology (141) 141
protein binding (141) 141
pyridines - administration & dosage (141) 141
antiviral agents - therapeutic use (139) 139
hiv (139) 139
care and treatment (138) 138
cell survival - drug effects (138) 138
antiviral agents (135) 135
mice, inbred c57bl (133) 133
cell line (129) 129
rats, wistar (125) 125
microbiology (124) 124
permeability (124) 124
polyethylene glycols - chemistry (124) 124
ritonavir (124) 124
drug stability (123) 123
drug carriers - chemistry (122) 122
pharmacology/toxicology (122) 122
biological availability (121) 121
hiv protease inhibitors - pharmacokinetics (121) 121
administration, oral (120) 120
antineoplastic agents - administration & dosage (120) 120
chromatography, high pressure liquid (119) 119
efficacy (118) 118
half-life (117) 117
medicine (117) 117
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3284) 3284
Japanese (31) 31
Russian (18) 18
French (12) 12
German (10) 10
Chinese (8) 8
Spanish (7) 7
Slovak (3) 3
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
... of approximately 1.8 log 10  copies ml −1 , and a pharmacokinetic/pharmacodynamic (PK/PD) relationship was identified and characterized. Furthermore, no NNRTI resistance... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
AIDS (London), ISSN 0269-9370, 2007, Volume 21, Issue 14, pp. 1899 - 1907
...: Non-blinded, single center, open-label pharmacokinetic study in HIV-infected women. Method: Twenty-seven women initiating combination antiretroviral therapy... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | VALIDATION | PREVENTION | PENETRATION | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | VIROLOGY | LIQUID-CHROMATOGRAPHY | pharmacokinetics | INFECTION | MACAQUES | TENOFOVIR | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 2019, Volume 85, Issue 7, pp. 1572 - 1584
...). We investigated the pharmacokinetics, safety and tolerability of EA-230 in healthy subjects using different administration strategies. METHODS... 
pharmacokinetics | immunomodulation | randomized clinical trial | phase I | EA‐230 | tolerability | EA-230 | OLIGOPEPTIDES | SEPSIS | HUMAN CHORIONIC-GONADOTROPIN | PEPTIDE | PREGNANCY | TUFTSIN | IMMUNE-SYSTEM | DISEASE | SEPTIC SHOCK | PHARMACOLOGY & PHARMACY | SUBUNIT | Index Medicus | Original
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2010, Volume 328, Issue 5981, pp. 1031 - 1035
Poor penetration of anticancer drugs into tumors can be an important factor limiting their effícacy. We studied mouse tumor models to show that a previously... 
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | NANOPARTICLES | INTEGRINS | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | IN-VIVO | DOXORUBICIN | PHAGE DISPLAY | VASCULAR-PERMEABILITY FACTOR | CELL | ENDOTHELIAL GROWTH-FACTOR | DELIVERY | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Antineoplastic agents | Drug therapy | Health aspects | Chemotherapy | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article
Clinical pharmacokinetics, ISSN 1179-1926, 2012, Volume 51, Issue 12, pp. 809 - 822
A previously published study of antiretroviral pharmacokinetics in the female genital tract of HIV-infected women demonstrated differing degrees of female genital tract penetration among antiretrovirals... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | PERFORMANCE LIQUID-CHROMATOGRAPHY | VARIABILITY | REVERSE-TRANSCRIPTASE INHIBITORS | HUMAN PLASMA | POPULATION PHARMACOKINETICS | QUANTIFICATION | ACTIVE ANTIRETROVIRAL THERAPY | CLINICAL-TRIALS | IMMUNODEFICIENCY-VIRUS TYPE-1 | PREVENTION | PHARMACOLOGY & PHARMACY | Reverse Transcriptase Inhibitors - blood | Humans | Pyridines - pharmacokinetics | Adenine - blood | Tenofovir | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Atazanavir Sulfate | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-HIV Agents - blood | Genitalia, Female - metabolism | Adenine - analogs & derivatives | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - pharmacokinetics | Organophosphonates - pharmacokinetics | Pyridines - blood | Models, Biological | Anti-HIV Agents - pharmacokinetics | HIV Infections - drug therapy | Premenopause - metabolism | HIV Infections - metabolism | Antiviral agents | Models | Research | Pharmacokinetics | Analysis | antiretrovirals | atazanavir | tenofovir | pharmacokinetics | pharmacokinetic-modelling | population-pharmacokinetics | HIV-infections | efavirenz | lamivudine
Journal Article
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 10/2011, Volume 39, Issue 10, pp. 1873 - 1882
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 2017, Volume 57, Issue 10, pp. 1305 - 1314
...‐state faldaprevir on the pharmacokinetics (PK) of a single dose of atorvastatin or rosuvastatin... 
faldaprevir | atorvastatin | rosuvastatin | drug–drug Interaction | COA REDUCTASE INHIBITOR | CHRONIC HEPATITIS-C | LIVER FIBROSIS | TRANSPLANT RECIPIENTS | INTERFERON-FREE | DRUG TRANSPORTERS | THERAPY | drug-drug Interaction | BI 201335 | GENOTYPE 1 INFECTION | PHARMACOLOGY & PHARMACY | PROTEASE INHIBITOR FALDAPREVIR | Atorvastatin Calcium - analogs & derivatives | Atorvastatin Calcium - blood | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Male | Healthy Volunteers | Oligopeptides - adverse effects | Thiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Drug Interactions | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Rosuvastatin Calcium - blood | Atorvastatin Calcium - adverse effects | Serine Proteinase Inhibitors - pharmacology | Atorvastatin Calcium - pharmacokinetics | Antiviral Agents - pharmacology | Rosuvastatin Calcium - pharmacokinetics | Cross-Over Studies | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Thiazoles - pharmacology | Oligopeptides - pharmacology | Rosuvastatin | Dosage and administration | Hepatitis C | Drug therapy | Pharmacokinetics | Analysis | Metabolites | Viruses | Cytochromes | Pharmacology | Hepatitis C virus | Drug dosages | Steady state
Journal Article